FDA Approves Three Updated COVID-19 Vaccines Targeting XFG Variant for 2026-2027 Season

The U.S. Food and Drug Administration (FDA) has approved updated formulations for three COVID-19 vaccines from Pfizer-BioNTech, Moderna, and Novavax, all designed to protect against the JN1-lineage XFG subvariant of SARS-CoV-2. These approvals provide clinicians with options ahead of the fall respiratory virus season, with the updated vaccines covering various age and risk-based indications.